Children’s Hospital Colorado preparing 25 new cancer trials after “breakthrough” law signed

Doctors at Children’s Hospital Colorado are hoping to launch as many as 25 new clinical trials in the next six months following a recently signed federal law opened the floodgates to test experimental cancer drugs for children. “The paediatric oncology community is really excited,” said Dr. Lia Gore, the director of Children’s Center for Cancer

Continue Reading

US approval for Gileads 3 in 1 hepatitis C treatment

The FDA has recently approved Gilead Sciences’ triple drug therapy, Vosevi, to treat hepatitis C Virus (HCV) as a back-up therapy for patients who cannot treat the virus with current drugs. The single-tablet triple therapy contains NS5B polymerase inhibitor sofosbuvir and NS5A inhibitor velpatasvir. Which are the two active ingredients in Gilead’s recently-approved two-drug HCV

Continue Reading

Remicade biosimilar – Renflexis receives approval from US regulators

US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications. Physicians will now be able to prescribe the drug for reducing signs and symptoms in patients with adult and paediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and

Continue Reading

Parker Institute, BMS and CRI announce partnership to accelerate immuno-oncology research

The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely with prominent Parker Institute and CRI scientists and researchers, soliciting clinical research

Continue Reading

Chemists make key advancements to simplify drug design and production

Researchers at Rice University, the University of Texas Southwestern Medical Center and Brigham Young University have discovered a one-step solution to make nitrogen-laden molecular precursors for the preparation of drugs and other bioactive molecules. Research announced this month in Science will simplify the process and cut the cost of creating key nitrogen-containing functional groups for

Continue Reading